Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10225361 | 0.97 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL12908851 | 0.94 | — | — | |
| SCHEMBL10092851 | 0.88 | — | — | |
| SCHEMBL15755715 | 0.79 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL14738149 | 0.79 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL23514890 | 0.79 | — | — | |
| SCHEMBL16731867 | 0.77 | — | — | |
| SCHEMBL16804410 | 0.77 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL23790320 | 0.77 | — | — | |
| SCHEMBL15755959 | 0.77 | ALDH1A1 (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218021-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | SINAI HEALTH SYSTEM (CA) | 2024-06-27 | — | — | US | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230159535-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-RE49338-E1 | Phthalazinone derivatives and manufacturing process thereof | IDIENCE CO., LTD. (KR) | 2022-12-20 | — | — | US | disclosed |
| US-20210277002-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-09-09 | — | — | US | disclosed |
| US-10709692-B2 | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) | DENALI THERAPEUTICS INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-9844550-B2 | Phtalazinone derivatives and manufacturing process thereof | ILDONG PHARM CO., LTD (KR) | 2017-12-19 | — | — | US | disclosed |
| US-20170182045-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | IL DONG HOLDINGS CO., LTD (KR) | 2017-06-29 | — | — | US | disclosed |
| US-9630956-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630956-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160222003-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | IL DONG HOLDINGS CO., LTD (KR) | 2016-08-04 | — | — | US | disclosed |
| US-20120027874-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120027874-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222003-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | PARP15, PARP10, PARP1 | ALDH1A1 1605/4885 |
| US-20120027874-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | ALDH1A1 3898/4885 |
| US-20240218021-A1 | CYCLIN INHIBITORS | CCNI, CCNC, CDK2 | ALDH1A1 2597/4885 |
| US-20170182045-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | PARP15, PARP10, NUDT5 | ALDH1A1 1576/4885 |
| US-10709692-B2 | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) | RIPK1, RIPK2, RIPK3 | ALDH1A1 4555/4885 |
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | WEE2, WEE1, KAT2A | ALDH1A1 1899/4885 |
| US-20230159535-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | ALDH1A1 3301/4885 |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | ALDH1A1 1726/4885 |
| US-20210277002-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | ALDH1A1 4079/4885 |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | ALDH1A1 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.